Background In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC). the role of maintenance therapy after first-line treatment with chemotherapy plus antiepidermal growth factor receptor (EGFR) monoclonal antibodies (MoAb) is still an object of debate. Methods We assessed the efficacy and safety of regorafenib as a switch maintenance strategy after upfront 5-fluorourac... https://megavitamines.shop/product-category/nac/